ReviewPlants (Basel, Switzerland)2023
New Insights into the Latest Advancement in α-Amylase Inhibitors of Plant Origin with Anti-Diabetic Effects.
Review in Plants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 144 citations in OpenAlex.
- Development of new imidazopyridine-based chalcones hybrids as potent antidiabetic and antioxidant agents: synthesis, in silico and in vitro evaluation.Scientific reports · 2026Article
- Morpho-molecular approach reveals a myco-endophyte, Aspergillus novoparasiticus CBS126849 (MTCC-13997) from the roots of Capparis decidua with therapeutic and enzymatic potential.Archives of microbiology · 2026Article
- GC-Ms, UHPLC-MS/MSChemistry & biodiversity · 2026Article
- Phytochemical Profiling and Evaluation of Antioxidant and Enzyme Inhibitory Activities of Selected EndemicFood science & nutrition · 2026Article
- Thiazolidinedione-triazole hybrids: design, synthesis, and biological evaluation as dual inhibitors of α-amylase and aldose reductase with antioxidant activity for antidiabetic therapy.Molecular diversity · 2026Article
- Article
- Integrated In Silico Prioritization of Antidiabetic Phytochemicals fromMolecules (Basel, Switzerland) · 2026Article
- Inhibition of Diabetes-Related Enzymes by Plant Secondary Metabolites: A Promising Therapeutic Strategy.Life (Basel, Switzerland) · 2026Review
- Phytochemical Analysis, GC-MS Chemical Profiling, and In Vitro Antidiabetic Evaluation of South AfricanCurrent issues in molecular biology · 2026Article
- Solvent-free microwave-assisted extraction: Enhancing bioactive molecules retention in citrus post-distillation residue using green extraction approach.Food chemistry: X · 2026Article
- Gap Analysis of Metabolic Conversions of Off-Flavors and Antinutrients in Plant-Based Substrates.Comprehensive reviews in food science and food safety · 2026Review
- Phytochemical Characterisation and Bioactivity ofMolecules (Basel, Switzerland) · 2026Article
- Phytochemical Profile and Bioactive Potential ofCurrent issues in molecular biology · 2026Article
- Integrated GC-MS Profiling and Phytosynthesis of MnOChemistry & biodiversity · 2026Article
- Green Synthesis and Bioactivity Evaluation of Silver Nanoparticles from Stevia rebaudiana and the Endophyte Aspergillus versicolor.Current microbiology · 2026Article
- Seasonal Variation in WildMolecules (Basel, Switzerland) · 2026Article
- Effects of salivary amylase gene copy number on metabolic health.Frontiers in nutrition · 2026Review
- Article
- Effect of Chemical Modifications on the Structure, Antioxidant, and Hypoglycemic Activity of Prunus Cerasifera Ehrh. Polysaccharides.Chemistry & biodiversity · 2026Article
- Therapeutic Potential of White Kidney Beans (Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The rising predominance of type 2 diabetes, combined with the poor medical effects seen with commercially available anti-diabetic medications, has motivated the development of innovative treatment approaches for regulating postprandial glucose levels. Natural carbohydrate digestion enzyme inhibitors might be a viable option for blocking dietary carbohydrate absorption with fewer side effects than manufactured medicines. Alpha-amylase is a metalloenzyme that facilitates digestion by breaking down polysaccharides into smaller molecules such as maltose and maltotriose. It also contributes to elevated blood glucose levels and postprandial hyperglycemia. As a result, scientists are being urged to target α-amylase and create inhibitors that can slow down the release of glucose from carbohydrate chains and prolong its absorption, thereby resulting in lower postprandial plasma glucose levels. Natural α-amylase inhibitors derived from plants have gained popularity as safe and cost-effective alternatives. The bioactive components responsible for the inhibitory actions of various plant extracts have been identified through phytochemical research, paving the way for further development and application. The majority of the findings, however, are based on in vitro investigations. Only a few animal experiments and very few human investigations have confirmed these findings. Despite some promising results, additional investigation is needed to develop feasible anti-diabetic drugs based on plant-derived pancreatic α-amylase inhibitors. This review summarizes the most recent findings from research on plant-derived pancreatic α-amylase inhibitors, including plant extracts and plant-derived bioactive compounds. Furthermore, it offers insights into the structural aspects of the crucial therapeutic target, α-amylases, in addition to their interactions with inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.